{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:31:14Z","timestamp":1790613074332,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among 1463 Candida glabrata isolates collected in 39 US hospitals, 91 (6.2%) were non\u2013wild type to \u22651 echinocandins (ECH-NWT) when tested by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpretative criteria. Rezafungin breakpoints established by the US Food and Drug Administration (FDA) were also applied. ECH-NWT isolates were noted in all US census divisions, and 71 (79.0% of ECH-NWT) carried FKS hot spot (HS) alterations. S663P in FKS2 HS1 (31 isolates) was the most common alteration, followed by substitutions\/deletions in position F659 in FKS2 HS1 (14 isolates) and S629P in FKS1 HS1 (9 isolates). Six isolates had substitutions in the HSs of FKS1 and FKS2, and 8 other alterations were noted in the 11 remaining isolates. When CLSI\/FDA breakpoints were applied, rezafungin was active against 97.5%\/95.3% and 59.3%\/23.9% of the overall C glabrata and ECH-NWT isolates, respectively. Anidulafungin, caspofungin, and micafungin inhibited 93.9%\/13.2%, 95.7%\/33.0%, and 95.6%\/29.7% of the overall C glabrata\/ECH-NWT isolates. Isolates that did not harbor FKS HS substitutions were more susceptible to echinocandins when compared with isolates with substitutions (47.4%\u2013100% and 4.2%\u201349.3%; lowest for anidulafungin and highest for rezafungin per the CLSI breakpoint). Isolates harboring the FKS2 HS1 S663P alterations were more resistant to echinocandins\u20143.2% susceptible (anidulafungin) to 35.5% (rezafungin CLSI breakpoint)\u2014when compared with other single alterations. Rezafungin dosing and pharmacokinetic\/pharmacodynamic characteristics allow for coverage of higher minimum inhibitory concentration values, making this agent an attractive option for some isolates that carry FKS alterations and still demonstrate rezafungin-susceptible minimum inhibitory concentration values.<\/jats:p>","DOI":"10.1093\/ofid\/ofae702","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:23:11Z","timestamp":1741130591000},"source":"Crossref","is-referenced-by-count":7,"title":["Activity of Rezafungin Against Echinocandin Non\u2013wild type <i>Candida glabrata<\/i> Clinical Isolates From a Global Surveillance Program"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, Iowa \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-1132","authenticated-orcid":false,"given":"Lalitagauri M","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, Iowa \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-1543","authenticated-orcid":false,"given":"John H","family":"Kimbrough","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, Iowa \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-5034","authenticated-orcid":false,"given":"Marisa","family":"Winkler","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, Iowa \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2025031112363321200_ofae702-B1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.12.1.80","article-title":"Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C albicans","volume":"12","author":"Fidel","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"2025031112363321200_ofae702-B2","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025031112363321200_ofae702-B3","doi-asserted-by":"crossref","first-page":"e01811-20","DOI":"10.1128\/JCM.01811-20","article-title":"Name changes for fungi of medical importance, 2018 to 2019","volume":"59","author":"Borman","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"suppl 1","key":"2025031112363321200_ofae702-B4","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025031112363321200_ofae702-B5","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jac\/dkac161","article-title":"Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications","volume":"77","author":"Rogers","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025031112363321200_ofae702-B6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jgar.2022.05.004","article-title":"Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression","volume":"29","author":"Castanheira","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2025031112363321200_ofae702-B7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025031112363321200_ofae702-B8","doi-asserted-by":"crossref","first-page":"e0244921","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2025031112363321200_ofae702-B9","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025031112363321200_ofae702-B10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/infdis\/jiae146","article-title":"Regulatory considerations in the approval of rezafungin (REZZAYO) for the treatment of candidemia and invasive candidiasis in adults","volume":"230","author":"Smith","year":"2024","journal-title":"J Infect Dis"},{"key":"2025031112363321200_ofae702-B11","article-title":"Antibacterial susceptibility test interpretive criteria","author":"Food and Drug Administration","year":"2024"},{"key":"2025031112363321200_ofae702-B12","doi-asserted-by":"crossref","first-page":"e0158423","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp in the ReSTORE phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-012-9551-x","article-title":"Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme","volume":"174","author":"Pfaller","year":"2012","journal-title":"Mycopathologia"},{"key":"2025031112363321200_ofae702-B14","volume-title":"M27 Ed4: reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"2025031112363321200_ofae702-B15","volume-title":"M27 M44S Ed3: performance standards for antifungal susceptibility testing of yeasts","author":"Clinical and Laboratory Standards Institute","year":"2022"},{"key":"2025031112363321200_ofae702-B16","volume-title":"M57s Ed4: epidemiological cutoff values for antifungal susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2022"},{"key":"2025031112363321200_ofae702-B17","doi-asserted-by":"crossref","first-page":"e00906-17","DOI":"10.1128\/AAC.00906-17","article-title":"Monitoring antifungal resistance in a global collection of invasive yeasts and molds: application of CLSI epidemiological cutoff values and whole-genome sequencing analysis for detection of azole resistance in Candida albicans","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/jof4030105","article-title":"Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata","volume":"4","author":"Healey","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"2025031112363321200_ofae702-B19","article-title":"Antimicrobial-resistant invasive candidiasis","author":"Centers for Disease Control and Prevention","year":"2024"},{"issue":"suppl 6","key":"2025031112363321200_ofae702-B20","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025031112363321200_ofae702-B21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance: an emerging clinical problem?","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"2025031112363321200_ofae702-B22","doi-asserted-by":"crossref","first-page":"e00161-17","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B23","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"2025031112363321200_ofae702-B24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/antibiotics9090539","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections","volume":"9","author":"Ghannoum","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025031112363321200_ofae702-B25","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1128\/AAC.06253-11","article-title":"Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B","volume":"56","author":"Hull","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B26","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1128\/AAC.03255-14","article-title":"Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance","volume":"58","author":"Pham","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B27","doi-asserted-by":"crossref","first-page":"e0172521","DOI":"10.1128\/aac.01725-21","article-title":"Echinocandins susceptibility patterns of 2,787 yeast isolates: importance of the thresholds for the detection of FKS mutations","volume":"66","author":"Desnos-Ollivier","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B28","doi-asserted-by":"crossref","first-page":"e0195921","DOI":"10.1128\/mBio.01959-21","article-title":"Multifactorial role of mitochondria in echinocandin tolerance revealed by transcriptome analysis of drug-tolerant cells","volume":"12","author":"Garcia-Rubio","year":"2021","journal-title":"mBio"},{"key":"2025031112363321200_ofae702-B29","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025031112363321200_ofae702-B30","doi-asserted-by":"crossref","first-page":"e02154-17","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B31","doi-asserted-by":"crossref","first-page":"e02614-17","DOI":"10.1128\/AAC.02614-17","article-title":"Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against Candida albicans and Candida glabrata","volume":"62","author":"Bader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"2025031112363321200_ofae702-B32","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025031112363321200_ofae702-B33","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: a novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell Microbiol"},{"key":"2025031112363321200_ofae702-B34","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031112363321200_ofae702-B35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14656566.2024.2331775","article-title":"An evaluation of rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis","volume":"25","author":"Sharma","year":"2024","journal-title":"Expert Opin Pharmacother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofae702\/62216127\/ofae702.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofae702\/62216127\/ofae702.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:30:48Z","timestamp":1741699848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae702\/8047337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae702","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,28]]},"article-number":"ofae702"}}